Innoviva

Innoviva INVA Stock

$18.41   0.000000%
Add to favorites
Market Cap
$1.31B
LOW - HIGH [24H]
$18.33 - $18.79
VOLUME [24H]
$1.15M
P/E Ratio
7.83
Earnings per share
$2.35
ISIN
US45781M1018
Price   Prediction

Innoviva Price Chart

Sorry, that's all we've gotfor now...

Innoviva (INVA) stock price today is 18.41 USD on Tech Market Large (0% on the day). Updated .

Innoviva INVA Financial and Trading Overview

Innoviva stock price 18.41 USD
Previous Close 18.41 USD
Open 18.41 USD
Bid 13.26 USD x 200
Ask 23.56 USD x 200
Day's Range 18.33 - 18.79 USD
52 Week Range 18.19 - 25.15 USD
Volume 1.15M USD
Avg. Volume 855.55K USD
Market Cap 1.31B USD
Beta (5Y Monthly) 0.369
PE Ratio (TTM) 7.834043
EPS (TTM) 2.35 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date September 8, 2015
1y Target Est 33.83 USD

INVA Valuation Measures

Enterprise Value 1.05B USD
Trailing P/E 7.834043
Forward P/E 8.330317
PEG Ratio (5 yr expected) 2.8
Price/Sales (ttm) 2.9855266
Price/Book (mrq) 1.1577888
Enterprise Value/Revenue 2.395
Enterprise Value/EBITDA 5.253

Trading Information

Innoviva Stock Price History

Beta (5Y Monthly) 0.369
52-Week Change -12.16%
S&P500 52-Week Change 8.67%
52 Week High 25.15 USD
52 Week Low 18.19 USD
50-Day Moving Average 20.48 USD
200-Day Moving Average 21.84 USD

INVA Share Statistics

Avg. Volume (3 month) 855.55K USD
Avg. Daily Volume (10-Days) 970.81K USD
Shares Outstanding 71.08M
Float 66.88M
Short Ratio 11.18
% Held by Insiders 1.02%
% Held by Institutions 109.63%
Shares Short 7.5M
Short % of Float 14.28%
Short % of Shares Outstanding 10.47%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1241:1000

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 44.13%
Operating Margin (ttm) 39.48%
Gross Margin 76.96%
EBITDA Margin 45.58%

Management Effectiveness

Return on Assets (ttm) 7.29%
Return on Equity (ttm) 18.01%

Income Statement

Revenue (ttm) 438.32M USD
Revenue Per Share (ttm) 5.95 USD
Quarterly Revenue Growth (yoy) -1.60%
Gross Profit (ttm) 337.37M USD
EBITDA 199.81M USD
Net Income Avi to Common (ttm) 193.44M USD
Diluted EPS (ttm) 2.35
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 590.06M USD
Total Cash Per Share (mrq) 8.3 USD
Total Debt (mrq) 331.04M USD
Total Debt/Equity (mrq) 29.1 USD
Current Ratio (mrq) 15.436
Book Value Per Share (mrq) 15.901

Cash Flow Statement

Operating Cash Flow (ttm) 183.46M USD
Levered Free Cash Flow (ttm) 121.16M USD

Profile of Innoviva

Country United States
State CA
City Burlingame
Address 1350 Old Bayshore Highway
ZIP 94010
Phone 650 238 9600
Website https://www.inva.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 159

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Q&A For Innoviva Stock

What is a current INVA stock price?

Innoviva INVA stock price today per share is 18.41 USD.

How to purchase Innoviva stock?

You can buy INVA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Innoviva?

The stock symbol or ticker of Innoviva is INVA.

Which industry does the Innoviva company belong to?

The Innoviva industry is Biotechnology.

How many shares does Innoviva have in circulation?

The max supply of Innoviva shares is 71.08M.

What is Innoviva Price to Earnings Ratio (PE Ratio)?

Innoviva PE Ratio is 7.83404300 now.

What was Innoviva earnings per share over the trailing 12 months (TTM)?

Innoviva EPS is 2.35 USD over the trailing 12 months.

Which sector does the Innoviva company belong to?

The Innoviva sector is Healthcare.

Innoviva INVA included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech Biotechnology Total Retu XNBI US 7414.87 USD —
-1.68
— — 7398.95 USD — 7631.86 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Global BuyBack Achievers DRBG US 2931.29 USD —
-1.64
— — 2928.3 USD — 2987.23 USD — — — —
us US Tech Global Select Market Com NQGS US 11139.01 USD —
-5.31
— — 11086.73 USD — 11742.47 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
$2.08T
Total marketcap
$148.67B
Total volume
BTC 57.84%   •   ETH 9.87%
Dominance
Select currency